EA200601796A1 - Pyrimidine derivatives for the treatment of anomalous cell growth - Google Patents

Pyrimidine derivatives for the treatment of anomalous cell growth

Info

Publication number
EA200601796A1
EA200601796A1 EA200601796A EA200601796A EA200601796A1 EA 200601796 A1 EA200601796 A1 EA 200601796A1 EA 200601796 A EA200601796 A EA 200601796A EA 200601796 A EA200601796 A EA 200601796A EA 200601796 A1 EA200601796 A1 EA 200601796A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
cell growth
pyrimidine derivatives
anomalous cell
mammals
Prior art date
Application number
EA200601796A
Other languages
Russian (ru)
Inventor
Майкл Джозеф Луццио
Джон Чарльз Кат
Original Assignee
Пфайзер Продактс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200601796(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пфайзер Продактс, Инк. filed Critical Пфайзер Продактс, Инк.
Publication of EA200601796A1 publication Critical patent/EA200601796A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Настоящее изобретение относится к соединению формулы (I), где R-Rтакие, как они определены в данном описании изобретения. Такие новые пиримидиновые производные полезны в лечении аномального клеточного роста, например рака, у млекопитающих. Данное изобретение также относится к способу применения таких соединений в лечении аномального клеточного роста у млекопитающих, в особенности людей, и к фармацевтическим композициям, содержащим такие соединения.The present invention relates to a compound of formula (I), wherein R-R are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

EA200601796A 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of anomalous cell growth EA200601796A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14
PCT/IB2005/001201 WO2005111023A1 (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
EA200601796A1 true EA200601796A1 (en) 2007-04-27

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601796A EA200601796A1 (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of anomalous cell growth

Country Status (27)

Country Link
EP (1) EP1751143A1 (en)
JP (1) JP4099212B2 (en)
KR (1) KR100886990B1 (en)
CN (2) CN102127058A (en)
AP (1) AP2241A (en)
AR (1) AR049097A1 (en)
AU (2) AU2005243397A1 (en)
BR (1) BRPI0511138A (en)
CA (1) CA2566707A1 (en)
CR (1) CR8749A (en)
EA (1) EA200601796A1 (en)
EC (1) ECSP066997A (en)
GE (1) GEP20104875B (en)
GT (1) GT200500113A (en)
IL (1) IL178828A0 (en)
MA (1) MA28583B1 (en)
MX (1) MXPA06011890A (en)
NL (2) NL1029045C2 (en)
NO (1) NO20064576L (en)
NZ (1) NZ550448A (en)
PA (1) PA8632601A1 (en)
PE (1) PE20060240A1 (en)
TN (1) TNSN06370A1 (en)
TW (1) TWI303635B (en)
UY (1) UY28894A1 (en)
WO (1) WO2005111023A1 (en)
ZA (1) ZA200608394B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566531A1 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EP1966207A2 (en) * 2005-12-21 2008-09-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP2146779B1 (en) * 2007-04-18 2016-08-10 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
WO2009012421A1 (en) * 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
US8461147B2 (en) * 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
SI2300013T1 (en) * 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2014174745A1 (en) * 2013-04-26 2014-10-30 国立大学法人京都大学 Eg5 INHIBITOR
CN109608444B (en) * 2018-11-27 2022-02-11 中国药科大学 Isoindolinone-containing ERK inhibitor and preparation method and application thereof
CN111732548B (en) * 2020-06-11 2022-06-17 浙江大学 N2-carbamyl aromatic ring-2-aminopyrimidine derivatives and medical application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL379330A1 (en) * 2002-12-20 2006-08-21 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
CN1953974A (en) 2007-04-25
AP2241A (en) 2011-06-01
ECSP066997A (en) 2007-02-28
JP4099212B2 (en) 2008-06-11
GT200500113A (en) 2006-01-10
CN102127058A (en) 2011-07-20
AU2009238255A1 (en) 2009-12-03
CA2566707A1 (en) 2005-11-24
TNSN06370A1 (en) 2008-02-22
TW200539871A (en) 2005-12-16
PE20060240A1 (en) 2006-04-01
PA8632601A1 (en) 2006-06-02
NL1031845A1 (en) 2006-07-31
JP2007537234A (en) 2007-12-20
UY28894A1 (en) 2005-12-30
AU2005243397A1 (en) 2005-11-24
TWI303635B (en) 2008-12-01
KR100886990B1 (en) 2009-03-04
NL1031845C2 (en) 2006-11-23
IL178828A0 (en) 2007-03-08
BRPI0511138A (en) 2007-11-27
AP2006003790A0 (en) 2006-10-31
ZA200608394B (en) 2008-05-28
NO20064576L (en) 2006-11-07
KR20070012477A (en) 2007-01-25
GEP20104875B (en) 2010-01-11
MA28583B1 (en) 2007-05-02
WO2005111023A1 (en) 2005-11-24
EP1751143A1 (en) 2007-02-14
NL1029045C2 (en) 2006-06-02
NL1029045A1 (en) 2005-11-15
MXPA06011890A (en) 2006-12-14
AR049097A1 (en) 2006-06-28
NZ550448A (en) 2010-11-26
CR8749A (en) 2006-12-05

Similar Documents

Publication Publication Date Title
EA200601796A1 (en) Pyrimidine derivatives for the treatment of anomalous cell growth
EA200801287A1 (en) Pyrimidine derivatives for the treatment of anomalous cell growth
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TNSN06074A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
EA200901250A1 (en) SULPHONYLAMID DERIVATIVES FOR THE TREATMENT OF ANOMALOUS GROWTH OF CELLS
EA200971104A1 (en) Derivatives of benzimidazole
MXPA06013164A (en) Pyrimidines derivatives for the treatment of abnormal cell growth.
EA200701808A1 (en) Derivatives of tetrahydroindolone and tetrahydroindazole
EA200800172A1 (en) 2,4-DIAMINOPYRIMIDINES AS AURORA INHIBITORS
NO20071642L (en) N-Benzenesulfonyl-substituted anilino-pyrimidine analogs
MXPA05012025A (en) Imidazo and thiazolopyridines as jak3 kinase inhibitors.
EA200800047A1 (en) DERIVATIVES OF PYRIMIDINE
NO20085176L (en) Phenyl substituted heteroaryl derivatives and use as anti-tumor agents
EA200500203A1 (en) NEW METHOD OF SYNTHESIS AND NEW CRYSTAL FORM OF AGOMELATIN AND PHARMACEUTICAL COMPOSITIONS THAT HERE CONTAINS
EA200801608A1 (en) DERIVATIVES OF BENZIMIDAZOLONIC CARBONIC ACID
ATE543803T1 (en) 3-Ä2-(3-AZYLAMINO-2-OXO-2H-PYRIDINE-1-YL)ACETYLAMINOÜ-4-OXOPENTANIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS
EA200701930A1 (en) Derivatives of pyrimidine for the treatment of hyperproliferative disorders
MXPA05010440A (en) Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b).
EA200702375A1 (en) UREA DERIVATIVES, METHODS FOR THEIR RECEPTION AND APPLICATION
EA200601065A1 (en) DERIVATIVES OF IMIDAZOL, METHODS OF THEIR PRODUCTION AND APPLICATION
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
TW200719889A (en) Amino acid derivatives
EA200600760A1 (en) NEW COMPOUNDS PHENILPYRIDILPIPERAZINE, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR0318521A (en) arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods